RESULTS: The percentages of patients who took part in sexual activity before undergoing RALP and 3, 6, 9, and 12 months after RALP were 47, 23, 29, 31, and 34%, respectively. Those of patients who took part in sexual intercourse before undergoing RALP and 3, 6, 9, and 12 months after RALP were 33, 6, 10, 10, and 10%, respectively. Both sets of values after undergoing RALP were significantly lower than those before undergoing RALP (Fig.1) . Sexual activity was not associated with the improvement of sexual function in Sexual Health Inventory for Men (SHIM) score. On the other hand, sexual activity was associated with the improvement of sexual function in EPIC score as with sexual intercourse (Fig.2) .
INTRODUCTION AND OBJECTIVES:
The Male Sexual Health Questionnaire (MSHQ), a validated scale for quantitative assessment of sexual dysfunction in men with benign prostatic hyperplasia (BPH), may provide a more objective assessment than spontaneous reporting of sexual adverse events (AEs). We recently reported a randomized study (FDC116115; NCT01777269) showing a significant reduction (worsening) in total MSHQ scores with dutasteride/tamsulosin fixed-dose combination therapy (DUT-TAM FDC) compared with placebo. No minimal clinically meaningful difference has been established for the MSHQ. The objective of this analysis was to evaluate the clinical relevance of total and subdomain MSHQ score changes by association with sexual AEs of special interest (AESIs) reported in the same study.
METHODS: This was a post hoc analysis of study FDC116115, which enrolled sexually active men aged !50 years with a diagnosis of BPH across 51 sites who were randomized 1:1 to receive oral DUT-TAM FDC (DUT 0.5 mg, TAM 0.4 mg, once daily) or placebo for 12 months. The cumulative distribution function for change from baseline in MSHQ total and domain scores was assessed. A MantelHaenszel test stratified by treatment was used to evaluate the association between worsening of MSHQ scores from baseline to month 12 with corresponding occurrence of sexual AESIs.
RESULTS: 489 patients were randomized (DUT-TAM FDC, n[243; placebo, n[246). Cumulative distribution plots for MSHQ total and domain scores at month 12 showed larger reductions in total MSHQ and ejaculation domain scores with DUT-TAM FDC than placebo. There was minimal difference between the groups in the plots for erection, sexual satisfaction, and desire domain scores. The majority of patients spontaneously reporting any sexual AESI (86% DUT-TAM FDC, 67% placebo) had a worsening of their MSHQ total score at month 12; this association was significant (P<.001) across both treatment groups. Patients treated with DUT-TAM FDC were more likely to report any sexual AESI at a threshold reduction of w10 points in total MSHQ score from baseline to month 12. Overall, most patients across both groups reporting ejaculation and erection AESIs, had worsening of the equivalent MSHQ domain score at month 12 (88%, P [.002 and 78%, P<.001, respectively) .
CONCLUSIONS: A reduction in the total MSHQ score was associated with greater likelihood of a sexual AESI, warranting further investigation. A clinically-relevant MSHQ threshold will enable clinicians to anticipate and proactively address potential sexual side effects of BPH therapy.
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